EUCTR2010-020450-33-ATActive, not recruitingPhase 1
Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO®
Institute of Specific Prophylaxis and Tropical Medicine0 sites60 target enrollmentStarted: May 28, 2010Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •adults (18-40 years and =65 years with no upper age limit), both sexes,
- •willingness to sign written informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
Exclusion Criteria
- •age below 18 years, age between 41 and 64 years;
- •prior japanese encephalitis, TBE, dengue, yellow fever or West e virus infection,
- •yellow fever vaccination within the last 10 years, TBE vaccination within the last 30 days;
- •vaccination against dengue or West e Virus;
- •current acute infection (body temperature above 37,9°C)
Investigators
Similar Trials
Active, not recruiting
Phase 1
Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot studyEUCTR2011-002928-41-ATMed. Uni. Wien, Klinik für Innere I52
Active, not recruiting
Not Applicable
Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccinatioEUCTR2008-005800-24-ATMedizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin84
Completed
Not Applicable
Investigation of the humoral and cellular immunity against SARS-CoV2 in patients after kidney transplantation in pandemic timesU07.1COVID-19, virus identifiedDRKS00024171niversitätsklinikum Köln46
Recruiting
Phase 4
Evaluation of vaccine response to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDSRBR-3wshg2mHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Active, not recruiting
Not Applicable
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) - mgus-vacc responsMonoclonal Gammopathy of Undetermined significanceEUCTR2010-022693-14-NLuniversity medical centre groningen